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Cre-recombinase-mediated excision of the TDP-43Q331K 
gene from motor neurons is shown to delay onset of motor 
symptoms and appearance of TDP-43-mediated aber-
rant nuclear morphology, and abrogate subsequent death 
of motor neurons. However, reduction of mutant TDP-43 
selectively in motor neurons did not prevent age-dependent 
degeneration of axons and neuromuscular junction loss, nor 
did it attenuate astrogliosis or microgliosis. Thus, disease 
mechanism is non-cell autonomous with mutant TDP-43 
expressed in motor neurons determining disease onset but 
progression defined by mutant acting within other cell types.
Keywords Amyotrophic lateral sclerosis (ALS) · TDP-
43 · Frontotemporal dementia (FTD) · RanGAP1 · Motor 
neuron · Non-cell autonomous · Neurodegeneration · 
Mouse model
Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal 
dementia (FTD) are progressive adult-onset neurodegen-
erative diseases with overlapping clinical and pathological 
features [34]. In both human patients and animal models of 
disease, motor neurons appear to be selectively vulnerable 
to age-dependent degeneration, despite nearly ubiquitous 
expression of an ALS-associated mutation in multiple cell 
types. Many hypotheses have been proposed to explain the 
selective vulnerability of motor neurons [34, 63], including 
a reduced level of relevant chaperone proteins that allows 
the accumulation of misfolded protein in motor neurons, 
relative to other cell types [15, 26, 62].
Expression in mice of ALS-linked mutations in ubiq-
uitously expressed superoxide dismutase (SOD1) pro-
duces progressive motor neuron disease. Using either 
Abstract Mutations in TDP-43 cause amyotrophic lat-
eral sclerosis (ALS), a fatal paralytic disease characterized 
by degeneration and premature death of motor neurons. 
The contribution of mutant TDP-43-mediated damage 
within motor neurons was evaluated using mice express-
ing a conditional allele of an ALS-causing TDP-43 mutant 
(Q331K) whose broad expression throughout the cen-
tral nervous system mimics endogenous TDP-43. TDP-
43Q331K mice develop age- and mutant-dependent motor 
deficits from degeneration and death of motor neurons. 
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Cre-recombinase mediated genetic approaches or deliv-
ery of a short hairpin RNA (shRNA) [16] or a microRNA 
[66] to lower mutant SOD1 synthesis, the age of disease 
onset is delayed by reduction of mutant SOD1 expression 
within motor neurons [9, 69] and precursors of oligoden-
drocytes [30], while rate of disease progression is delayed 
by reducing mutant SOD1 synthesized by microglia [5, 9] 
or astrocytes [16, 67, 69]. A direct non-cell autonomous 
toxicity from astrocytes towards motor neurons has also 
been shown in multiple in vitro co-culture systems using 
astrocytes expressing mutant SOD1 or derived from ALS 
patients [7, 14, 21, 39, 50].
A majority (~90%) of ALS cases occurs sporadically 
with no known familial pattern of inheritance or associ-
ated gene mutation. Importantly, pathological comparisons 
between sporadic and inherited cases have revealed a com-
mon biochemical signature of ubiquitinated lesions con-
taining TAR DNA binding protein (TDP-43) [1, 44], with 
the appearance of TDP-43-positive inclusions in almost all 
ALS cases, except in those caused by mutation in SOD1 
or FUS [36, 56]. The discovery of ALS-linked mutations 
in TDP-43 within a subset of familial cases demonstrated a 
causative role for this protein in disease pathogenesis [12, 
60].
Similar to the ubiquitously expressed SOD1, TDP-43 is 
expressed in most cell types. Whether TDP-43 mis-accu-
mulation leads to pathology affecting the same cell types 
as those affected by SOD1 mutants is not known. Previous 
studies have provided conflicting evidence for a potential 
non-cell autonomous contribution of mutant TDP-43 to 
motor neuron degeneration. Neuronal inducible overex-
pression of TDP-43M337V was sufficient to cause rapidly 
fatal disease in rats [23], demonstrating an apparent cell-
intrinsic component to toxicity mediated by high levels of 
TDP-43. However, the same team reported that restricted 
overexpression of TDP-43M337V induced in astrocytes was 
also sufficient to cause motor neuron degeneration in vivo 
[64] and led to upregulation of neurotoxic factors in vitro 
[22]. Despite this, astrocytes derived from glial precursor 
cells isolated from mice expressing TDP-43A315T at three-
fold higher than endogenous TDP-43 in the central nerv-
ous system were not toxic to wild-type motor neurons in an 
in vitro co-culture assay [20]. Since TDP-43 protein aggre-
gates appear in the majority of sporadic ALS cases, under-
standing the cell type specific contributions of TDP-43 to 
disease pathogenesis has broad implications that could 
direct therapeutic design for more than the subset of famil-
ial patients carrying specific mutations.
Our prior work established that ALS-linked mutant 
TDP-43Q331K causes progressive age-dependent motor 
neuron degeneration without a requirement for nuclear-
cytosolic relocalization or protein aggregation [2]. 
Rather, moderate level expression of mutant TDP-43Q331K 
led to widespread splicing defects throughout the spinal 
cord and brain. Mutant TDP-43Q331K expressing animals 
developed age-dependent lower motor neuron disease, 
progressive decline in motor performance, and reduced 
hindlimb strength, accompanied by ~30% loss in inner-
vated neuromuscular junctions, motor axons, and motor 
neurons.
Given the motor defects observed in mice expressing 
mutant TDP-43Q331K broadly throughout the central nerv-
ous system, we have now tested whether mutant TDP-
43Q331K synthesized within motor neurons drives disease 
onset or progression. Selective excision of the mutant 
encoding TDP-43Q331K transgene from motor neurons is 
found to delay age of disease onset with no effect on dis-
ease progression after onset despite complete preserva-
tion of motor neuron numbers even at late ages. Glial cell 
activation was unaffected, consistent with mutant TDP-43 
expression within glial cells and/or other surrounding neu-
rons contributing to non-cell autonomous motor neuron 
degeneration and death.
Materials and methods
Generation of transgenic mice expressing mutant 
TDP‑43Q331K throughout the central nervous system, 
with levels selectively lowered in motor neurons
Transgenic mice which express a deletable human TDP-
43 transgene carrying a mutation at Q331K broadly within 
the central nervous system were described in [2] and 
deposited at Jackson Laboratories as B6N.Cg-Tg(Prnp-
TARDBP*Q331K)103Dwc/J. For selective expression of 
Cre recombinase in motor neurons, VChAT-Cre mice in a 
C57Bl6 background [40, 69] were bred to the floxed TDP-
43Q331K line 103. To assess the specificity of Cre activity 
within motor neurons, mice were bred to Rosa-26 reporter 
mice which ubiquitously express a β-galactosidase 
transgene that can only be translated upon Cre-mediated 
recombination to remove a premature stop cassette, also in 
a C57Bl6 background [59, 69]. Breeding schemes paired 
TDP-43Q331K animals with double transgenic Rosa-26/
VChAT-Cre animals to produce litters with triple trans-
genic offspring. Upon tissue collection at various ages, 
genotypes for all animals were reconfirmed using fresh tail 
biopsies.
RNA extraction and RT‑qPCR
Total RNA was isolated using Trizol (Invitrogen) extrac-
tion, and mRNA levels were determined by qRT-PCR using 
the iQSYBR Green supermix (Bio-Rad).
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Protein extraction and immunoblotting
Tissues were homogenized in a glass dounce homogenizer 
in lysis buffer (800 μL per spinal cord) (20 mM Hepes 
pH 7.4, 5 mM MgCl2, 150 mM KCl, 0.5 mM DTT, with 
freshly added protease inhibitors and RNAseOUT). An ali-
quot of the lysate was set aside for RNA extraction using 
trizol, while the rest was processed for protein extraction. 
Lysates were centrifuged at 2000 g for 10 min to remove 
myelin, the lysis buffer was supplemented with NP-40 for 
a final concentration of 1% NP-40, and then centrifuged at 
high speed, 15,000 rpm, for 15 min. Equal amounts of each 
sample (30 μg protein) were loaded onto a 12.5% Tris–HCl 
gel (Bio-Rad, Criterion). Following transfer to nitrocel-
lulose, the immunoblot was sequentially probed with an 
antibody that recognizes both human and mouse TDP-43 
(Proteintech #12892, 1:1000), the Myc-tag (Millipore 4A6, 
1:1000), or Hsp90 (Cell Signaling C45G5, 1:1000).
Immunofluorescence
Tissue preparation for immunofluorescence was performed 
as previously described [2]. Anesthetized animals were 
transcardially perfused with 4% (vol/vol) paraformalde-
hyde in phosphate-buffered saline pH 7.4, then tissues 
were cryopreserved in 30% (wt/vol) sucrose, and embed-
ded in TissueTek OCT (Sakura). Following cryosection-
ing of spinal cord into 30 μm-thick sections, free floating 
sections were selected from the same well per animal for 
each experiment and immunostained with the indicated 
antibodies. In brief, free floating sections were washed in 
PBS three times before incubation in blocking solution 
containing PBS with 1.5% (wt/vol) BSA and 0.5% Tween-
20 for 1 h at room temperature. Sections were incubated 
in primary antibodies (detailed in Supplementary Materi-
als) in PBS, 0.3% (wt/vol) Triton-X 100 overnight at room 
temperature, and then washed three times in PBS before 
incubation with secondary antibodies in PBS, 0.3% (wt/
vol) Triton-X 100 for 1 hr at room temperature. After incu-
bation with DAPI (1 μg/ml) and a final wash with PBS, 
sections were mounted onto glass slides and allowed to dry 
overnight before coverslipping with ProLong Gold anti-
fade mounting media (Invitrogen). For detection of primary 
antibodies, donkey anti-rabbit, anti-mouse, or anti-goat 
Cy3, Cy5, or Alexa-488 conjugated antibodies (Jackson 
ImmunoResearch) were used at a 1:500 dilution.
Immunohistochemistry
Tissue sections were cut from blocks of formalin-fixed 
paraffin embedded ALS tissue, obtained from Dr. John 
Ravits’ bank collection (control patient #83 and #65). 
The spinal cord sections of patients harboring TDP-43 
mutations (Pt #284 and #203) as well as control #150 
were obtained from the MRC London Neurodegen-
erative Diseases Brain Bank (King’s College London) 
(see table below). Seven µm-thick tissue sections were 
stained with an antibody against RanGAP1 (ab92360) 
from Abcam (Cambridge, MA, USA). Slides were 
stained on a Ventana Discovery Ultra (Ventana Medi-
cal Systems, Tucson, AZ, USA). Antigen retrieval was 
performed using Tris–EDTA based cell conditioning 
solution (CC1) for 40 min at 95 °C. The primary anti-
body was incubated on the sections at 1:300 dilution for 
32 min at 37 °C followed by UltraMap (Ventana) and 
DAB detection. Slides were rinsed, dehydrated through 
alcohol and xylene, and coverslipped. Imaging was per-
formed on Nanozoomer slide scanner (Hamamatsu) at 
the UCSD microscopy core.
Patient # Age at 
death (years)
Sex Diagnosis Genotype Post-mortem 
delay + 
interval (h)
Reference
65 82 M NORMAL N/A 4*
83 63 F NORMAL N/A 4*
A150/01 40 M NORMAL N/A 40
A284/13 57 M ALS TARDBP  
M337V
74 [60]
A203/12 23 F ALS TARDBP  
Y374X +  
FUS P525L
125 [32]
* Post-mortem interval only (post-mortem delay not available)
Animal behavior
Animal studies were carried out under protocols approved 
by the Institutional Animal Care and Use Committee of 
the University of California San Diego (IACUC protocol 
#S00225), and were in compliance with the Association for 
Assessment of Laboratory Animal Care guidelines for ani-
mal use. For behavior experiments, TDP-43Q331K and TDP-
43Q331K/VChAT-Cre animals were compared to contempo-
raneously produced littermates, either containing or lacking 
the Rosa26-LacZ reporter.
Accelerating rotarod
To test motor performance, cohorts of age-matched, gen-
der-matched transgenic animals and littermate controls 
were tested for the time to fall on an accelerating rotarod 
apparatus (UGO Basile; 2–40 rpm). Animals were tested 
over three trials with a maximum time of 300 s per trial 
at each age (3, 6, 10–12, 15–16, ≥18 months). Latency to 
fall was recorded in seconds once the mice fell from the 
bar, or rotated once around the bar, according to previous 
studies [2, 10, 37]. Following a 1-day training session, 
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Fig. 1  Reduction of mutant TDP-43 in motor neurons without alter-
ing total transgene levels. a Scheme of the three transgenic mouse 
lines used in this study: a floxed construct expressing mutant TDP-
43Q331K throughout the nervous system driven by the prion promoter, 
VChAT-Cre targeting Cre to motor neurons, and the Rosa26 reporter 
to detect Cre activity. b Enzymatic Cre activity occurs specifically 
within lumbar spinal cord motor neurons, as shown by representa-
tive micrographs illustrating immunostaining with antibodies against 
β-galactosidase (β-gal) and ChAT in 2-month-old animals. Scale 
bar 200 µm. c Quantification of ChAT positive motor neurons that 
express β-gal in (b). Cre-excision occurred in about 50% of motor 
neurons in both VChAT-Cre and TDP-43Q331K/VChAT-Cre groups 
(n ≥ 3 animals per group). d Representative confocal micrographs 
of the ventral horn of lumbar spinal cord from 2-month-old animals 
showing TDP-43Q331K in motor neurons using antibodies against 
the transgene encoded Myc tag and ChAT. Scale bar 200 µm for all 
images, with enlarged inset panels on the right. e The percentage 
of ChAT positive cells containing TDP-43Q331K (white arrows) was 
quantified from n ≥ 3 animals per genotype. About 45% of motor 
neurons show reduced TDP-43Q331K expression in TDP-43Q331K/
VChAT-Cre animals. f, g Total levels of TDP-43Q331K are simi-
lar between TDP-43Q331K and TDP-43Q331K/VChAT-Cre groups at 
2 months of age, supporting the selective expression of Cre within 
motor neurons. f mRNA levels of human and mouse TDP-43 were 
assessed by qRT-PCR using species-specific primers, shown as fold 
change over controls (Non-Tg and VChAT-Cre) (n ≥ 5 per group). 
g Protein levels of human and mouse TDP-43 in total spinal cord 
lysates were determined by immunoblotting with an antibody recog-
nizing both human and mouse TDP-43
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motor performance was assessed in three trials each 
day over the course of three consecutive days. The data 
shown are the average of nine values per animal across 
the three sessions, ±SEM from n ≥ 4 animals per group 
at each time point. Animals were studied longitudinally 
over time, and the graph in Fig. 2a (and Supplementary 
Fig. 2a) depicts the same animals followed from 3- to 
15–18 months of age, with a reduced n per group over 
time as animals were collected for tissue analysis.
Analysis of hindlimb clasping
An observer blinded to the genotypes scored animals as 
being either affected or unaffected by hindlimb clasp-
ing. Mice were classified as displaying hindlimb clasping 
if they displayed retraction of the hindlimbs after being 
lifted by the tail for 30 s or less. Prior to tissue collection, 
all animals were video recorded to document hindlimb 
clasping and other phenotypes. A percentage of animals 
affected at 10–12 or 19–24 months is shown in Fig. 2b, 
with n ≥ 12 per group.
Quantification of lower motor neurons
ChAT-positive ventral horn motor neurons were quan-
tified from at least 20 sections per animal, spaced 
360 μm apart throughout the lumbar spinal cord. Data 
were acquired from n > 3 animals per genotype at 
10–12 or 19–24 months of age and are shown as the 
average of the total number of motor neurons counted 
divided by the number of sections for each animal, 
±SEM.
Morphometric analysis and quantification of L5 root 
motor axons
Mice were perfused transcardially with 4% paraformalde-
hyde in 0.1 M Sorenson’s phosphate buffer, pH 7.4. Roots 
from lumbar level 5 of the spinal cord (L5) were dissected 
from n > 3 animals per genotype at 10–12 months and at 
19–24 months of age, and preserved in fixative at 4 °C until 
embedding. Roots were embedded in Epon-Araldite as pre-
viously described in [47]. Thick sections (0.75 μm) were 
prepared and stained with toluidine blue for analysis by 
light microscopy. For animals in each age group, cross sec-
tions of axons were analyzed using BioQuant software and 
axonal diameters were graphed as a size distribution curve.
Quantification of neuromuscular junctions 
and morphology
Floating 40 μm-thick longitudinal sections of gastrocne-
mius muscle were incubated in blocking solution [PBS, 
0.5% vol/vol Tween 20, 1.5% wt/vol BSA] for 4 h at room 
temperature. Sections were then incubated with polyclonal 
synaptophysin antibody (ThermoFisher, SP11, 1:50 dilu-
tion) in PBS, 0.3% Triton-X 100 at room temperature over-
night. The following day, sections were washed in PBS and 
incubated with donkey anti-rabbit Cy3 (Jackson Immu-
noResearch) and α-bungarotoxin Alexa488 (ThermoFisher, 
B13422) at 1:500 for 1 h, and then with fluoromyelin red 
(ThermoFisher, F34652) at 1:300 for 30 min. The sections 
were further washed with PBS, mounted, and dried over-
night before coverslipping. For each animal, about ten sec-
tions were analyzed for quantification of neuromuscular 
junctions (shown as average ± SEM). Morphology was 
scored from >300 NMJs per animal, and endplates that 
appeared fragmented or small were scored as abnormal. An 
observer blinded to animal genotype performed quantifica-
tion and morphology scoring. Representative images were 
acquired across a 25-μm Z-stack acquired at 20× mag-
nification using a Nikon Eclipse laser scanning confocal 
microscope, and maximum projection images were obtained 
using Nikon Elements software (shown in Fig. 3c).
Confocal microscopy and image analysis
All confocal images were acquired on a Nikon Eclipse 
laser scanning confocal microscope using Nikon Elements 
software. For each immunostaining experiment, confocal 
acquisition parameters were determined optimally below 
saturation level and kept consistent across all samples. 
Images used for quantification in Figs. 1c, e, 4b, c, and 
5f, g were acquired at 20× magnification. Representative 
images in Figs. 4a, 5a–e (right panels) were acquired at 
60× magnification.
VChAT‑Cre excision efficiency determined by β‑gal/ChAT 
or Myc/ChAT staining
Co-localization of β-gal or Myc with ChAT staining was 
determined from multiple 10 μm-thick Z-stack images 
of the lumbar spinal cord acquired at 20× magnification 
on a Nikon confocal microscope. The percent of ChAT-
positive cells containing β-gal staining were counted from 
>10 maximum projection images taken across the lumbar 
region, scoring at least 200 cells per animal in n ≥ 3 mice 
per group. The percent of ChAT positive cells containing 
bright nuclear Myc (human TDP-43Q331K) staining was 
analyzed using Volocity software to quantify fluorescence 
intensity of Myc within each ChAT positive cell. An aver-
age of 230 ChAT positive cells were counted per animal 
and scored as either Myc positive or negative relative to 
a standard Myc fluorescence intensity threshold across 
samples. To determine percentages of both β-gal/ChAT 
912 Acta Neuropathol (2017) 133:907–922
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and Myc/ChAT overlap, n ≥ 3 animals were analyzed per 
group at each time point.
Extent of nuclear morphology aberrations based 
on RanGAP1/Myc/ChAT staining
To assess nuclear morphology in motor neurons, lum-
bar spinal cord sections were immunostained with Ran-
GAP1, Myc, and ChAT antibodies. Identical observations 
were made for RanGAP1 aberrations using two different 
antibodies for RanGAP1 (rabbit polyclonal H-180 and goat 
polyclonal N-19 from Santa Cruz Biotechnology) and Myc 
(mouse monoclonal 4A6 from Millipore or rabbit poly-
clonal from Sigma). For each animal, between 5 and 9 sec-
tions of the lumbar spinal cord were imaged using a 20× 
objective for acquisition across a 10 μm-thick Z-stack. 
Maximum projection images were scored by an observer 
blinded to genotypes. All ChAT positive motor neurons 
were first counted in each image, then scored as containing 
normal or aberrant nuclear morphology, based on RanGAP1 
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Fig. 2  Reduction of mutant TDP-43 within motor neurons delays 
onset of motor impairment in TDP-43Q331K mice, but not disease pro-
gression, despite age-dependent preservation of motor neuron num-
bers. a Motor performance (using rotarod) of TDP-43Q331K/VChAT-
Cre animals was significantly improved compared to TDP-43Q331K 
animals at 6 and 10 months of age, but declined by 15 months 
reaching poor motor performance close to TDP-43Q331K. Data are 
shown as average ± SEM with n = 10–30 mice per group for ages 
3–15 months and n = 4–14 animals per genotype at 18 months. 
*P < 0.05, **P < 0.005, and ***P < 0.0001 using an unpaired t 
test. b The percentage of animals displaying a clasping phenotype 
was protected in TDP-43Q331K/VChAT-Cre animals at 10 months, 
but not at 19 months of age (at 10 months, n > 12 animals, and at 
19 months, n > 18, in TDP-43Q331K and TDP-43Q331K/VChAT-Cre 
animals, respectively). Statistical analysis was performed using 
Fisher’s exact test (*P = 0.025, **P < 0.005, ***P < 0.0001). c, d 
Motor neuron loss was rescued in TDP-43Q331K/VChAT-Cre animals 
compared to TDP-43Q331K animals. c Quantification of ChAT posi-
tive motor neurons (average per section ± SEM, n ≥ 3 in controls, 
and n ≥ 5 animals in TDP-43Q331K and TDP-43Q331K/VChAT-Cre 
groups; ***P ≤ 0.0006 and **P = 0.004). d Representative confo-
cal micrograph of ChAT-positive α-motor neurons in lumbar spinal 
cords from TDP-43Q331K transgenic mice at 19 months of age. Scale 
bar 50 µm. n ≥ 2 in controls, and n ≥ 3 animals in TDP-43Q331K and 
TDP-43Q331K/VChAT-Cre groups
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staining, and scored as positive or negative for Myc levels 
(transgene) from four to six sections per animal (n > 50 
cells each, n > 4 animals per group). Nuclear morphologi-
cal aberrations were defined by lack of circularity of the 
nucleus and/or presence of invaginations or wrinkles around 
the nuclear perimeter using the RanGAP1 antibody. Rep-
resentative images for Fig. 4a and Supplementary Fig. 3b 
were acquired at 60× magnification across a 15 μm-thick 
Z-stack, and a maximum projection image is shown.
Astrogliosis and microgliosis determined by GFAP or Iba1 
fluorescence intensity
For quantification of GFAP and Iba1 staining, at least 
four 20× magnification Z-stack images were analyzed 
throughout the ventral horn of each animal. Nikon Ele-
ments Software was used to determine the average fluo-
rescence intensity (A.U.) across a region of interest around 
the gray matter in maximum projection images. Values 
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Fig. 3  Reduction of mutant TDP-43 within motor neurons only par-
tially delays degeneration of motor axons and neuromuscular junc-
tions. a Representative micrograph of motor axons in the lumbar L5 
motor root at 10 or 19 months of age. Scale bar 25 µm. b Quanti-
fication of total motor axons in the lumbar L5 motor root at 10 or 
19 months of age (average ± SEM, n = 6 in controls, and n ≥ 3 
animals in TDP-43Q331K and TDP-43Q331K/VChAT-Cre groups; 
*P < 0.04, **P < 0.009, and ***P = 0.0001 using an unpaired t test). 
c Representative neuromuscular junctions from non-transgenic, TDP-
43Q331K and TDP-43Q331K/VChAT-Cre animals. Muscle acetylcho-
line receptor endplates were labeled with α-bungarotoxin, and motor 
axons (synaptic motor axon terminals and myelinated axons) were 
marked by synaptophysin antibody and fluoromyelin red, respec-
tively. Scale bar 100 µm. d Quantification of average neuromuscu-
lar junctions per section ± SEM, n = 3; *P < 0.04, **P < 0.003. e 
Assessment of neuromuscular junction morphology during aging. 
Morphology was scored in >300 NMJs per animal, and abnormal 
morphology included fragmented or small NMJs; average ± SEM, 
n = 3; *P < 0.02, ***P < 0.0006
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were normalized to the average value in control animals at 
24 months and shown as the average ± SEM.
Statistical analyses
Differences between two groups were determined by an 
unpaired t test, using GraphPad Prism Software. The thresh-
old for significance was set as P ≤ 0.05. Alternatively, Fish-
er’s exact test was used to determine significance for the per-
centage of animals affected by hindlimb clasping (Fig. 2b).
Results
Motor neuron‑specific reduction of mutant TDP‑43 
in mice expressing mutant TDP‑43 broadly 
throughout the central nervous system
Transgenic mice expressing a Myc-tagged ALS-linked 
Q331K mutant human TDP-43 at 1.2 times the normal level 
of TDP-43 throughout the central nervous system, includ-
ing in motor neurons, oligodendrocytes and astrocytes, 
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Fig. 4  The TDP-43 mutant-dependent nuclear morphology defects 
in motor neurons of mice and ALS patients harboring TDP-43 muta-
tions are delayed upon reduction of mutant TDP-43 within mouse 
motor neurons. a, b Age-dependent increased nuclear morphology 
aberrations in motor neurons from mutant TDP-43Q331K mice, which 
was significantly delayed but not prevented with disease progression 
upon motor neuron specific excision of the transgene in TDP-43Q331K/
VChAT-Cre animals. a Representative confocal micrographs of 
nuclear membrane morphology in lumbar spinal cord motor neurons, 
revealed by RanGAP1 immunostaining in ChAT-positive cells. Green 
arrowheads indicate examples of motor neurons with nuclear aberra-
tions. Scale bar 10 µm. b Quantification of ChAT positive motor neu-
rons with aberrant nuclear morphology revealed by RanGAP1 immu-
nostaining (average ± SEM, n ≥ 4 animals per genotype at each 
timepoint). c Quantification of aberrant RanGAP1 containing nuclei 
that are TDP-43Q331K positive in lumbar spinal cord motor neurons 
at 19–24 months (n ≥ 6 animals from each group in non-transgenic, 
TDP-43Q331K, and TDP-43Q331K/VChAT-Cre). d Aberrant nuclear ring 
shape in motor neurons in the lumbar spinal cord anterior horn of 
ALS patients harboring TDP-43 mutations. RanGAP1 immunostain-
ing shows an irregular nuclear membrane in motor neurons from 
mutant TDP-43 patients (n = 2), compared to large round nuclei in 
motor neurons from control patients (n = 3). Scale bar 50 µm
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were previously shown to develop progressive adult-onset 
motor neuron disease [2]. The TDP-43Q331K transgene 
(flanked by loxP sites) is inactivatable by action of the Cre 
recombinase. To test the degree to which motor phenotypes 
were caused by cell intrinsic damage from mutant TDP-43 
expressed within motor neurons, the TDP-43Q331K animals 
were bred to VChAT-Cre mice that have previously been 
shown to postnatally express Cre recombinase selectively 
within motor neurons [40, 69] (Fig. 1a). Excision efficiency 
and specificity of the TDP-43Q331K transgene was initially 
determined using the Rosa26 reporter strain which ubiqui-
tously expresses a β-galactosidase transgene preceded by 
a floxed stop cassette and only expresses β-galactosidase 
in cells in which Cre recombinase has previously been 
activated [59]. By 2 months of age, Cre-mediated recom-
bination in TDP-43Q331K/VChAT-Cre/Rosa26 mice was 
seen in 50% of choline acetyltransferase (ChAT)-positive 
motor neurons throughout the lumbar spinal cord (Fig. 1b, 
c, Supplementary Fig. 1a, b), consistent with previous 
reports [40]. Also as expected, Cre-activated excision 
was selectively found only within motor neurons, with 
β-galactosidase activity restricted to ventral horn motor 
neurons (Supplementary Fig. 1a).
Finally, by evaluating the expression pattern of mutant 
TDP-43 in the ventral horn of lumbar spinal cords, exci-
sion efficiency of the actual TDP-43Q331K transgene was 
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Fig. 5  A non-cell autonomous contribution of mutant TDP-43Q331K 
to disease progression: reduction of mutant TDP-43Q331K within 
motor neurons does not alter neuroinflammation during disease pro-
gression. a Broad expression of the human TDP-43Q331K transgene in 
glial cells including oligodendrocytes and astrocytes, but not micro-
glia. Oligodendrocytes (CC1 antibody in (a), astrocytes (GFAP anti-
body in (b), and microglia (Iba1 antibody in (c) were identified by 
immunofluorescence in spinal cords from 12-month-old TDP-43Q331K 
animals using antibodies for cell type-specific markers. Arrows high-
light glial cells (in red) containing TDP-43Q331K positive nuclei (in 
green). Dashed outlines correspond to the boundary between gray 
and white matter. Scale bar 50 μm. d, e Representative micrographs 
of lumbar spinal cords from VChAT-Cre, TDP-43Q331K and TDP-
43Q331K/VChAT-Cre animals at late stages of disease processed for 
immunofluorescence using an antibody detecting activated astrocytes 
(GFAP) (d) or activated microglia (Iba1) (e). Scale bar 200 μm, 
with enlarged inset panels on the right. f, g Astrogliosis and micro-
gliosis were quantified by measuring GFAP (f) or Iba1 (g) fluores-
cence intensity from confocal images in the lumbar spinal cord of 12 
or 19-month-old animals (n ≥ 3 in TDP-43Q331K and TDP-43Q331K/
VChAT-Cre; *P < 0.05, **P < 0.005, and ***P < 0.0001 using an 
unpaired t test)
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measured to be 45% (Fig. 1d, e, Supplementary Fig. 1c, d) 
in TDP-43Q331K/VChAT-Cre animals. Excision was selec-
tive to motor neurons, as no excision of TDP-43Q331K was 
found in sensory neurons in the dorsal horn or glial cells 
(Supplementary Fig. 1e). VChAT-Cre inactivation of the 
TDP-43Q331K transgene did not significantly alter overall 
levels of mutant TDP-43 expression within the central nerv-
ous system (CNS), as determined by measuring TDP-43 
mRNA (Fig. 1f) and protein (Fig. 1g) levels in total spinal 
cord extracts. Consistent with previous reports establishing 
a mechanism for TDP-43 autoregulation [3, 4, 48], the lev-
els of endogenous mouse TDP-43 were reduced compared 
to non-transgenic animals.
Motor neuron‑specific reduction of mutant TDP‑43 
levels delays onset of motor deficits
To determine the contribution of mutant TDP-43-depend-
ent damage within motor neurons to disease pathogenesis, 
motor performance was evaluated longitudinally. Age-
dependent motor deficits in TDP-43Q331K mice (relative 
to non-transgenic littermates) initiated prior to 3 months 
of age and the deficits increased during aging (Fig. 2a), 
as previously reported [2]. In contrast, the motor perfor-
mance of TDP-43Q331K/VChAT-Cre animals was nearly 
unaffected up to 10 months of age (Fig. 2a, Supplementary 
Fig. 2a, with a latency to fall of 160 s, compared to 191 s 
in non-transgenic animals, n = 29 and 17, respectively). 
Reduction of TDP-43Q331K synthesis within motor neurons 
delayed the appearance of a hindlimb clasping motor phe-
notype that developed in >80% of TDP-43Q331K animals by 
10 months (Fig. 2b). Thus, motor neuron-specific reduc-
tion of mutant TDP-43 delays onset of significant motor 
deficits.
Reduction of mutant TDP‑43 within motor neurons 
prevents age‑dependent motor neuron death, but only 
modestly delays degeneration of motor axons 
and neuromuscular junctions
Although disease initiation was delayed, disease in the 
TDP-43Q331K/VChAT-Cre animals reached a similar dis-
ease state to the TDP-43Q331K mice by 18 months of age 
(Fig. 2a, Supplementary Fig. 2a). Nevertheless, eliminat-
ing TDP-43Q331K synthesis within individual motor neurons 
almost completely prevented the 30% loss of lumbar spinal 
cord α-motor neurons (27 ± 1 ChAT-positive motor neu-
rons per section in TDP-43Q331K/VChAT-Cre, n = 12, com-
pared with 21 ± 1 ChAT-positive motor neurons in TDP-
43Q331K, n = 9, P < 0.001 and 28 ± 1 ChAT-positive motor 
neurons in non-transgenic littermates, n = 6) (Fig. 2c, d).
Despite complete rescue of motor neuron cell bod-
ies, however, degeneration of motor axons (measured in 
L5 roots) was only modestly inhibited in TDP-43Q331K/
VChAT-Cre animals compared to TDP-43Q331K mice, both 
at onset and at later stages of disease (averages of 662 and 
508 motor axons, respectively, compared to 921 in non-
transgenic controls, n = 6, P < 0.001 for TDP-43Q331K com-
pared to controls, or P < 0.04 for TDP-43Q331K/VChAT-
Cre compared to TDP-43Q331K at 10 months) (Fig. 3a, b, 
Supplementary Fig. 2b, c). Examination of the remaining 
motor axons revealed degenerating axons, vacuolization, 
and myelin defects in both TDP-43Q331K and TDP-43Q331K/
VChAT-Cre animals (Fig. 3a), with a modest protection in 
TDP-43Q331K/VChAT-Cre animals at onset, but this ben-
efit was not sustained with aging (Fig. 3a). Mutant TDP-
43-dependent loss of the large-caliber α-motor axons 
(with axonal size >5.5 µm) was only partially alleviated at 
10 months in TDP-43Q331K/VChAT-Cre and did not reach 
numbers close to those in non-transgenic animals (Supple-
mentary Fig. 2b). Furthermore, the age-dependent atrophy 
of the remaining α-motor axons was similar to that in TDP-
43Q331K (Supplementary Fig. 2c).
Quantification of postsynaptic neuromuscular junctions 
in the gastrocnemius muscle using α-bungarotoxin staining 
revealed a significant degree of protection in TDP-43Q331K/
VChAT-Cre animals at 10–12 months, in contrast to the 
35% reduction in the number of neuromuscular endplates 
seen in TDP-43Q331K animals (Fig. 3d, n = 3, P < 0.02 for 
TDP-43Q331K compared to controls, and P < 0.02 for TDP-
43Q331K/VChAT-Cre compared to TDP-43Q331K). How-
ever, this protection was not sustained at 19–24 months 
(Fig. 3c, d, n = 3, P < 0.003 for TDP-43Q331K/VChAT-
Cre compared to controls). Morphological examination of 
neuromuscular junctions further indicated abnormalities 
including fragmented or small endplates in TDP-43Q331K 
animals (Fig. 3e), which were significantly attenuated at 
10–12 months but not prevented at later stages of disease in 
TDP-43Q331K/VChAT-Cre animals (Fig. 3e, 33% of NMJs 
with aberrant morphology in TDP-43Q331K/VChAT-Cre 
compared to 65% in TDP-43Q331K, n = 3, P < 0.0005 at 
10–12 months of age). Therefore, motor neuron-specific 
reduction of mutant TDP-43Q331K was not sufficient to 
abrogate defects in motor axons, neuromuscular junc-
tions, and behavioral performance at late stages of disease, 
despite nearly complete preservation of motor neuron cell 
bodies.
TDP‑43Q331K expression within motor neurons 
contributes to nuclear aberrations
Defects in nuclear membrane structure or nucleocyto-
plasmic transport have been reported in SOD1-mediated 
toxicity in the CNS of ALS patients [33] and mouse 
models [42, 70], and more recently in disease caused 
by the hexanucleotide repeat expansion in C9orf72 [17, 
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27, 71, 72]. Given the diminished motor performance in 
aged TDP-43Q331K/VChAT-Cre animals despite absence 
of motor neuron death, we examined the integrity of the 
nuclear membrane in the remaining motor neurons. Age-
dependent aberrations in nuclear morphology, including 
nuclear membrane invaginations (Fig. 4a, green arrows), 
were observed as early as 2 months of age in lumbar spi-
nal cord motor neurons of TDP-43Q331K animals com-
pared to non-transgenic mice (n = 4) (Fig. 4a, b, Supple-
mentary Fig. 3a and movie 1).
In contrast, motor neuron-specific reduction of mutant 
TDP-43Q331K significantly delayed the appearance of 
RanGAP1 aberrations in ChAT positive motor neurons 
of TDP-43Q331K/VChAT-Cre animals (Fig. 4a, b; 8.5% in 
TDP-43Q331K vs 3.8%, in TDP-43Q331K/VChAT-Cre, n = 7 
vs 5 animals, respectively, P = 0.043). Nevertheless, 
by 19 months, the extent of motor neurons with aberrant 
nuclear morphology (scored as shown in Fig. 4a, green 
arrows), in the TDP-43Q331K/VChAT-Cre mice was almost 
equivalent to that of TDP-43Q331K animals (Fig. 4b; 11 and 
9%, respectively; n ≥ 8), thus correlating with severity of 
the motor performance (Fig. 2a). Most of the motor neu-
rons with RanGAP1 aberrations (including invaginations 
in the nuclear membrane–Fig. 4a, Supplementary Fig. 3a; 
movie 1) expressed TDP-43Q331K (Fig. 4c, Supplemen-
tary Fig. 3b, green arrow). Nevertheless, one-fourth of the 
motor neurons with aberrations in RanGAP1 lacked mutant 
TDP-43 (Supplementary Fig. 3b, white arrows). In animals 
expressing wild-type human TDP-43 at total levels close 
to endogenous in a normal mouse [2], nearly all motor 
neurons maintained normal nuclei at 19 months of age 
(Fig. 4b, green bar), as in non-transgenic animals (Supple-
mentary Fig. 3b). Cytosolic foci containing RanGAP1 were 
present in young animals, and appeared to increase in size 
during aging (Fig. 4a), but the number of motor neurons 
containing foci did not differ between genotypes or during 
disease progression (Fig. 4a, Supplementary Fig. 3c).
Defects in nuclear membrane morphology were also 
found in lumbar spinal cords of ALS patients harboring a 
mutation in TDP-43 (Fig. 4d). Immunohistochemistry for 
RanGAP1 in the anterior horn revealed a smaller irregu-
lar ring shape around nuclei in mutant TDP-43 patients 
(n = 2), compared to large round nuclear membrane in 
motor neurons from controls (n = 3). Consistent with 
observations in animals (Fig. 4a), cytosolic RanGAP1-pos-
itive foci were observed in both patients and controls, and 
an increase in their size appears to correlate with increased 
age (Fig. 4d). Together, these data suggest that nuclear 
membrane morphology, as visualized by RanGAP1 stain-
ing, can distinguish healthy motor neurons from degener-
ating motor neurons, and these defects correlate with poor 
functionality of surviving motor neurons in TDP-43Q331K/
VChAT-Cre animals at late stages of disease.
Reduction of mutant TDP‑43Q331K within motor 
neurons does not alter neuroinflammation
TDP-43Q331K was widely expressed in the CNS and accu-
mulated in most oligodendrocytes (Fig. 5a, arrows) and 
astrocytes (Fig. 5b, arrows), but not microglia (Fig. 5c) 
(scored by immunofluorescence using the cell-type spe-
cific markers CC1, GFAP and Iba1, respectively). Remark-
ably, age-dependent activation of astrocytes (Fig. 5d) 
and microglia (Fig. 5e) in ventral horn of spinal cords of 
TDP-43Q331K animals (scored by GFAP and Iba1 immu-
noreactivity, respectively; Fig. 5f, g) was indistinguishable 
irrespective of whether mutant TDP-43 was expressed by 
motor neurons or not, both at young and old ages.
Discussion
One of the key discoveries of the past decade is that ALS-
like disease pathogenesis from ubiquitously expressed 
mutant SOD1 is non-cell autonomous [9]. Mutant SOD1 
synthesis within motor neurons [9, 69] and precursors of 
oligodendrocytes [30] drives disease onset, but mutant-
mediated damage within astrocytes [67, 69] and microglia 
[5, 9] drives rapid disease progression. To this, we have 
now established that ALS-mutant linked TDP-43 mutations 
expressed at moderate levels in a pattern mimicking endog-
enous TDP-43 also cause toxicity in a non-cell autonomous 
manner. Eliminating mutant TDP-43Q331K synthesis in a 
proportion of motor neurons delayed disease onset, reduced 
aberrant nuclear morphology in those neurons at early dis-
ease stages, and almost eliminated age-dependent acceler-
ated death of those motor neurons. Nevertheless, despite 
nearly complete rescue of motor neuron loss, deficits in 
motor performance at later disease stages—accompa-
nied by motor axon degeneration, neuromuscular junction 
loss, and increased nuclear morphology aberrations within 
motor neurons—were unaffected, as was the timing of sus-
tained activation of both astrocytes and microglia.
Our findings add to the growing body of evidence 
uncoupling motor neuron cell death from overall ALS dis-
ease course. In mutant SOD1 mouse models, genetic inter-
ventions which successfully prevented motor neuron cell 
death either by modulating levels of apoptotic factors [19, 
54], elevating chaperones [52], or by rescuing mitochon-
drial calcium buffering capacity [47], were ineffective in 
altering disease course or prolonging lifespan. Similarly, 
rescuing motor neuron death in mutant FUS-mediated dis-
ease does prevent motor deficits and axonal damage during 
aging [55].
A convergence of recent evidence has implicated errors 
in nucleo/cytoplasmic transport as a component of normal 
aging [11] as well as several neurodegenerative disorders 
918 Acta Neuropathol (2017) 133:907–922
1 3
[13], including ALS/FTD [8, 49], Huntington’s disease 
(Cleveland and Lagier-Tourenne, personal communication) 
[35, 43, 68], and other repeat expansion models [38, 51]. 
Studies in yeast [27] and flies [61] have identified compo-
nents of nuclear transport as modifiers of toxicity in models 
expressing mutant TDP-43, or the C9orf72 hexanucleotide 
repeat expansion [17, 71]. Altered distribution of importins 
has been described in motor neurons of mice expressing 
ALS-linked mutation in SOD1 [70], as have aberrations in 
RanGAP1 localization in C9orf72 patients [71] and irreg-
ularities in the nuclear membrane of cells with TDP-43 
pathology in sporadic ALS patients [33]. Mutations in the 
mRNA nuclear export factor Gle1 have also been identified 
in rare cases of ALS [28], and recently expression of TDP-
43 fragments prone to aggregation has been reported to 
cause mRNA retention in the nuclei of cultured cells [68].
To these earlier efforts, our findings suggest that TDP-
43 aggregation is not required to drive nuclear morphol-
ogy aberrations as accumulation of mutant TDP-43 to 
only about the normal level of endogenously expressed 
TDP-43 in both neurons and glial cells drives progressive 
motor neuron disease with specific loss of a third of lower 
motor neurons, despite the absence of cytosolic accumula-
tion of protein aggregates (nuclear or cytoplasmic) and loss 
of nuclear TDP-43 at any age [2]. Thus, our data provide 
in vivo evidence that 1) ALS-linked mutant TDP-43 causes 
age-dependent defects in nuclear membrane morphology 
(as indicated by RanGAP1 staining) not only in mouse 
motor neurons (correlating with motor functionality), but 
also in ALS patients harboring TDP-43 mutations, and 2) 
motor neuron-specific reduction of mutant TDP-43 signifi-
cantly delays the appearance of such defects and of motor 
performance deficits. It is noteworthy that nuclear aberra-
tions have also been reported in other ALS model systems 
[17, 27, 33, 42, 70–72], as well as other neurodegenerative 
diseases including Huntington’s disease (Cleveland and 
Lagier-Tourenne, personal communication), suggesting that 
nuclear morphology aberrations could be a general hall-
mark of neurodegeneration, possibly indicative of dysfunc-
tional neurons before their degeneration. How ALS-linked 
mutations in TDP-43 provoke alterations in RanGAP1 dis-
tribution is not established, and additional efforts are now 
needed to determine the underlying mechanism(s) and to 
test whether those are widely applicable to sporadic disease.
Prior studies have established non-cell autonomous toxic-
ity of mutant SOD1 from microglial cells [6, 9], oligoden-
drocytes [29, 30], and astrocytes [67, 69] (reviewed in Ref. 
[25]). Whether non-cell autonomous neuronal-glial signal-
ing is critical in TDP-43 causing disease is not yet estab-
lished. While mutant astrocytes (derived from glial precur-
sors isolated from transgenic TDP-43A315T mice [20] or from 
patient-induced pluripotent stem cells (iPSCs) harboring the 
TDP-43M337V mutation [57]) were not toxic to co-cultured 
wild-type mouse motor neurons, conditioned medium from 
TDP-43A315T mouse astrocytes [53] or microglia treated with 
recombinant TDP-43 mutants [73] triggered motor neuron 
death. Additionally, mutant TDP-43-mediated toxicity in 
mutant TDP-43 motor neurons was not enhanced by co-cul-
tured mutant astrocytes derived from iPSCs [57]. However, 
while transplanted glial precursor cells expressing mutant 
TDP-43A315T had no effect on motor neuron death or behav-
ioral phenotypes in wild-type rats [20], astrocyte-specific 
expression of mutant TDP-43M337V caused rapid fatal motor 
deficits within a month after induction of the transgene in 
transgenic rats [64]. Similarly, widespread overexpression 
of wild-type TDP-43 through an AAV9-mediated viral intra-
venous delivery in neonatal rats provoked rapid mortality 
in less than 1 month with only a mild (14%) loss of motor 
neurons, consistent with TDP-43-dependent alterations in 
motor neuron functionality independent of cell death, and/or 
contribution(s) of the surrounding cells including glia [65].
Our evidence strongly supports that mutant TDP-
43-mediated disease is non-cell autonomous. While most 
of the motor neurons with nuclear defects were mutant 
TDP-43 positive, one-fourth of them did not express the 
mutant protein, suggesting that damage to those nuclei 
is mediated by mutant TDP-43 expression in other cell 
types surrounding the motor neurons. Given the wide 
expression of mutant TDP-43, and that astrogliosis and 
microgliosis were not attenuated by mutant TDP-43 gene 
excision from motor neurons, toxicity must also be medi-
ated from a mutant acting in non-motor neurons as a 
contributor to motor deficits associated with age. Simi-
larly, FUS-mediated disease in mice where one copy of 
endogenous FUS was replaced by a mutant form of FUS 
restricted to the cytoplasm is also non-cell autonomous 
[55]. Altogether, non-cell autonomous toxicity is likely to 
be widely applicable in ALS pathogenesis. Perhaps most 
importantly, therapies specifically targeting motor neu-
rons have promise to delay early stages of disease, but 
it seems unlikely that they will suffice to extend overall 
survival, unless non-neuronal cells are also targeted.
The mechanisms underlying non-cell autonomous tox-
icity mediated by mutant TDP-43 are not known. TDP-43 
has been reported to be secreted via exosomes from neu-
rons [24], which could corroborate the hypothesis, so far 
untested in vivo, that TDP-43 proteinopathy propagates 
cell to cell [45]. TDP-43 proteins can be detected in CSF of 
ALS patients [18, 31, 46], suggesting that TDP-43 may be 
present in the CNS extracellular space. Addition of mutant 
TDP-43 protein fragments to cultured microglia did induce 
a receptor-mediated proinflammatory signaling response 
which was neurotoxic [73] possibly through passive diffu-
sion of TDP-43 [upon cleavage and/or post-translation mod-
ification] or release extracellularly during cell death [58]. 
However, the latter pathway is unlikely as motor neuron 
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death was prevented in our TDP-43Q331K animals even at 
late ages. One underlying mechanism would be that mutant 
TDP-43 expressing glial cells and/or other surrounding neu-
rons may release yet unidentified factors that are selectively 
toxic for motor neurons, as has been proposed in mutant 
SOD1-mediated disease [39, 41]. Another alternative mech-
anism for the non-cell autonomous component to disease 
progression could be altered neuronal connectivity, given 
the expression of mutant TDP-43 within other neuronal sub-
types and widespread splicing defects [2].
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